Effectiveness of Palivizumab in High-risk Infants and Children: A Propensity Score Weighted Regression Analysis

• Published in: The Pediatric infectious disease journal Vol. 36; no. 8; p. 699
• Main Authors: Anderson, Evan J, Carosone-Link, Phyllis, Yogev, Ram, Yi, Jumi, Simões, Eric A F
• Format: Journal Article
• Language: English
• Published: United States 01.08.2017
• Subjects: Antiviral Agents - therapeutic use; Case-Control Studies; Female; Humans; Infant; Infant, Newborn; Infant, Premature; Male; Palivizumab - therapeutic use; Propensity Score; Prospective Studies; Regression Analysis; Respiratory Syncytial Virus Infections - drug therapy; Respiratory Syncytial Virus Infections - epidemiology; Respiratory Syncytial Virus, Human
• DOI: 10.1097/INF.0000000000001533

Infants with premature birth ≤35 weeks gestational age, chronic lung disease of prematurity and congenital heart disease are at an increased risk for lower respiratory tract infections and hospitalization from respiratory syncytial virus (RSV), which has been shown in randomized trials to be prevented by palivizumab. However, palivizumab effectiveness (PE) has not been studied in a large clinical setting. A multicenter study among high-risk US and Canadian children younger than 24 months hospitalized with lower respiratory tract infection and whose nasopharyngeal aspirates were tested for human metapneumovirus (HMPV) and RSV were the subjects of the trial. We conducted a test-negative case-control study in these subjects to determine PE. We used an inverse propensity score weighted (IPSW) multiple logistic regression model to adjust PE. Palivizumab was used in 434 (51%) of 849 eligible children. RSV was identified in 403 (47%) children. The unadjusted PE was 43% [95% confidence interval (CI), 34%-51%)]. After IPSW adjustment, the adjusted PE was 58% (95% CI, 43%-69%). Palivizumab prevented intensive care unit admissions (PE, 62%; 95% CI, 35%-78%). PE for 29-35 weeks gestational age and ≤6 months of chronologic age without chronic lung disease of prematurity or congenital heart disease was 74% (95% CI, 56%-85%). Using a test-negative case-control design with RSV molecular detection, palivizumab is shown to prevent RSV hospitalizations and intensive care unit admissions in high-risk infants.